Neurodevelopmental Processes in the Prefrontal Cortex Derailed by Chronic HIV-1 Viral Protein Exposure

Kristen A. McLaurin, Hailong Li, Rosemarie M. Booze * and Charles F. Mactutus *

Citation: McLaurin, K.A.; Li, H.; Booze, R.M.; Mactutus, C.F. Neurodevelopmental Processes in the Prefrontal Cortex Derailed by Chronic HIV-1 Viral Protein Exposure. Cells 2021, 10, 3037. https://doi.org/10.3390/cells10113037

Received: 30 August 2021
Accepted: 3 November 2021
Published: 5 November 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Abstract: Due to the widespread access to, and implementation of, combination antiretroviral therapy, individuals perinatally infected with human immunodeficiency virus type 1 (HIV-1) are living into adolescence and adulthood. Perinatally infected adolescents living with HIV-1 (pALHIV) are plagued by progressive, chronic neurocognitive impairments; the pathophysiological mechanisms underlying these deficits, however, remain understudied. A longitudinal experimental design from postnatal day (PD) 30 to PD 180 was utilized to establish the development of pyramidal neurons, and associated dendritic spines, from layers II-III of the medial prefrontal cortex (mPFC) in HIV-1 transgenic (Tg) and control animals. Three putative neuroinflammatory markers (i.e., IL-1β, IL-6, and TNF-α) were evaluated early in development (i.e., PD 30) as a potential mechanism underlying synaptic dysfunction in the mPFC. Constitutive expression of HIV-1 viral proteins induced prominent neurodevelopmental alterations and progressive synaptodendritic dysfunction, independent of biological sex, in pyramidal neurons from layers II-III of the mPFC. From a neurodevelopmental perspective, HIV-1 Tg rats exhibited prominent deficits in dendritic and synaptic pruning. With regards to progressive synaptodendritic dysfunction, HIV-1 Tg animals exhibited an age-related population shift towards dendritic spines with decreased volume, increased backbone length, and decreased head diameter; parameters associated with a more immature dendritic spine phenotype. There was no compelling evidence for neuroinflammation in the mPFC during early development. Collectively, progressive neuronal and dendritic spine dysmorphology herald synaptodendritic dysfunction as a key neural mechanism underlying chronic neurocognitive impairments in pALHIV.

Keywords: adolescence; development; dendritic spines; human immunodeficiency virus type 1; prefrontal cortex; neuroinflammation

1. Introduction

Reports of children diagnosed with acquired immune deficiency syndrome (AIDS) occurred early in the pandemic [1,2]. Invariably, the disease was associated with high mortality rates [3]. However, with widespread access to, and implementation of, combination antiretroviral therapy (cART), pediatric human immunodeficiency virus type 1 (HIV-1) evolved from a fatal disease to a chronic disease (e.g., [4,5]). Consequently, the epidemiological features of pediatric HIV-1 have shifted, resulting in a growing population of perinatally infected adolescents living with HIV-1 (pALHIV). Indeed, approximately 2.78 million children and adolescents (0–19 years of age) are living with either perinatally or horizontally acquired HIV-1 [6]. Despite the disproportionate number of adolescents affected by HIV-1 worldwide, neurodevelopmental outcomes of pALHIV remain understudied [7].

Neurodevelopment, a dynamic, albeit protracted, process beginning during the gestational period and continuing through late adolescence, refers to the maturation of neural circuits that influence cognitive functioning (for review, [8]). Early pre- and postnatal brain development occurs via a precisely orchestrated and timed series of events, including neuronal production, migration, and differentiation, as well as myelination and synaptogenesis [8]; events which permit the establishment of neural circuits. Subsequent regressive
events, including programmed cell death [9,10], synaptic pruning [11,12], and dendritic pruning [13], aid in the refinement of neural circuits resulting in the formation of mature connections. Notably, the time course of such progressive and regressive events varies considerably across the cerebral cortex, whereby the prefrontal cortex (PFC) is one of the last to mature.

Whereas the basic cytoarchitecture of the PFC is defined by birth in humans (for review, [14]) and postnatal day (PD) 10 in rodents [15], its fine development continues through adolescence and young adulthood. Specifically, following neuronal proliferation and migration, cortical nerve cells extend their axons, undergo dendritic arborization, and form dendritic spines [16], enabling the assembly of immature neural circuits. The initial patterning of neural circuits in the PFC reflects exuberant connectivity, evidenced by the formation of an excessive number of synaptic contacts; synaptic contacts which are subsequently pruned during adolescence and young adulthood [11,12], coinciding with the development of higher-order cognitive processes. Chronic HIV-1 viral protein exposure may disrupt these events, fundamentally altering neurodevelopment in the PFC resulting in profound progressive neurocognitive impairments [17,18].

Indeed, chronic neurocognitive impairments [19] are a highly prevalent [20] and deleterious consequence of perinatally acquired HIV-1. Cross-sectional studies have provided a wealth of knowledge on chronic neurocognitive impairments, characterized by prominent deficits in cognitive functions that are dependent upon the integrity of the PFC (e.g., processing speed [21], attention [22], and executive function [23]). Evaluating neurodevelopmental outcomes, however, necessitates the utilization of a longitudinal experimental design; extrapolating cross-sectional findings to developmental processes is inferentially fraught [24]. Thus, repeated evaluation of neurocognitive function across time has been essential for establishing the progressive nature of chronic neurocognitive impairments associated with perinatally acquired HIV-1 [17,18,25]. Longitudinal experimental designs, however, remain underutilized for the investigation of the pathophysiological mechanisms underlying progressive chronic neurocognitive impairments, albeit with the exception of a recent manuscript [26].

To address this knowledge gap, two interrelated aims were investigated. First, a longitudinal experimental design (PD 30 to PD 180) was utilized to establish the development of pyramidal neurons, and associated dendritic spines, from layers II-III of the medial PFC (mPFC) in the HIV-1 transgenic (Tg) rat. Profound synaptodendritic loss and/or dysfunction has been observed in HIV-1 seropositive individuals [27,28] and biological systems used to model key aspects of HIV-1 (e.g., [18,29,30]); neurodevelopmental alterations in pyramidal neurons and/or dendritic spines, however, have not been systematically evaluated. Given the fundamental role of experience on neuronal and dendritic spine morphology (e.g., [31,32]), synaptodendritic alterations were evaluated in HIV-1 Tg and control animals with no prior cognitive or behavioral testing. Second, neuroinflammatory markers (i.e., IL-1β, IL-6, and TNF-α) were evaluated in the PFC at PD 30 to evaluate a potential mechanism underlying synaptodendritic dysfunction (e.g., IL-6: [33]).

2. Materials and Methods

2.1. Animals

Control (Fischer F344/N; Envigo Laboratories Inc., Indianapolis, IN, USA) animals were delivered to the animal vivarium and pair- or group-housed with animals of the same sex until sacrifice. HIV-1 Tg animals were bred on a Fischer F344/N background at the University of South Carolina by pairing a control female with an HIV-1 Tg male. Originally reported in 2001 by Reid et al. [34], the transgene integral to the HIV-1 Tg rat contains a gag and pol deleted provirus regulated by the human viral promotor. HIV-1 viral proteins are expressed throughout the body (e.g., blood, lymph nodes, spleen) and in the central nervous system constitutively throughout development [34,35]. Specifically, the HIV-1 viral proteins Tat, gp120, nef, and vif are expressed in multiple brain regions, including the prefrontal cortex, striatum, and hippocampus [35]. Furthermore, HIV-1 mRNA expression
exhibits a restricted and region-specific distribution, whereby abundant expression was observed in the mPFC [36]. The HIV-1 Tg rat, therefore, affords a biological system to examine synaptodendritic alterations following chronic HIV-1 viral protein exposure.

At approximately PD 24, HIV-1 Tg animals were weaned and pair- or group-housed with animals of the same sex until sacrifice. To preclude violation of the independence of observations assumption, the goal was to sacrifice no more than two rats (i.e., one male and one female) from each litter for an individual time point.

AAALAC-accredited facilities and guidelines established in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health were utilized for the maintenance of HIV-1 Tg and control animals. Animal vivarium environmental conditions were targeted at: 21 °C ± 2 °C, 50% ± 10% relative humidity and a 12-h light:12-h dark cycle with lights on at 0700 h (EST). The Institutional Animal Care and Use Committee (IACUC) at the University of South Carolina approved (25 March 2019) the project protocol (Federal Assurance, #D16-00028).

2.2. Experimental Design

A schematic of the experimental design is illustrated in Figure 1. In Experiment 1 (Neurodevelopmental Alterations in the mPFC), a time-sequential longitudinal experimental design was utilized, whereby HIV-1 Tg and control animals were sacrificed every 30 days from PD 30 to PD 180 to examine pyramidal neurons, and associated dendritic spines, from layers II-III of the mPFC using a ballistic labeling technique. In Experiment 2 (Neuroinflammatory Markers in the mPFC), HIV-1 Tg and control animals were sacrificed at PD 30 to evaluate three neuroinflammatory markers, including IL-1β, IL-6, and TNF-α.

A

Experiment #1: Neurodevelopmental Alterations in the Medial Prefrontal Cortex

Age of Sacrifice for Ballistic Labeling

- Postnatal Day 30
- Postnatal Day 60
- Postnatal Day 90
- Postnatal Day 120
- Postnatal Day 150

- Postnatal Day 180

B

Experiment #2: Neuroinflammatory Markers in the Medial Prefrontal Cortex

Age of Sacrifice for Evaluation of IL-1β, IL-6 and TNF-α

- Postnatal Day 30

Figure 1. Experimental Design. Notably, Experiment 1 (A) utilized a time-sequential longitudinal experimental design. A cross-sectional experimental design was implemented for Experiment 2 (B).

2.3. Experiment #1: Neurodevelopmental Alterations in the Medial Prefrontal Cortex (mPFC)

Pyramidal neurons, and associated dendritic spines, from layers II-III of the mPFC were examined to establish neurodevelopmental alterations in the mPFC. HIV-1 Tg and control animals were sacrificed every 30 days from PD 30 to PD 180 utilizing samples sizes of n = 40 for each age (i.e., Control: Male, n = 10, Female, n = 10; HIV-1 Tg: Male, n = 10, Female, n = 10). Ages were selected based on deficits observed in previous imaging [26] and cognitive [17,37,38] studies. Specifically, the earliest timepoint (i.e., PD 30) was selected following reports that presence of the HIV-1 transgene induced alterations in brain volume
The study endpoint (i.e., PD 180) reflects an age whereby the HIV-1 Tg rat exhibits prominent neurocognitive impairments relative to control animals (e.g., [17,37,38]).

2.3.1. Body Weight

Body weight, a measurement of somatic growth, was assessed immediately prior to sacrifice. Independent of biological sex, HIV-1 Tg animals weighed significantly less than control animals from PD 30 to PD 180.

Body weight for both male and female animals, independent of genotype, was well-described by a one-phase association (Supplementary Figure S1; $R^2 \geq 0.86$). For male animals, presence of the HIV-1 transgene significantly altered the plateau of the function ($F(1,106) = 14.1, p \leq 0.001$), but not the rate of growth (i.e., no statistically significant effect of genotype on the rate constant, $K (p > 0.05)$). For female animals, HIV-1 Tg animals exhibited a significantly lower y-intercept ($F(1,108) = 10.4, p \leq 0.001$) and plateau ($F(1,108) = 7.2, p \leq 0.01$), but no statistically significant differences in the rate of growth ($p > 0.05$). At sacrifice, therefore, there was strong evidence for the relative health of the HIV-1 Tg rat.

2.3.2. Estrous Cycle Tracking

A vaginal lavage was conducted immediately prior to sacrifice to evaluate the current estrous cycle stage. Cellular cytology was examined in vaginal smears, as previously described [39], under a 10x light microscope. The predominant cell type was utilized to determine the estrous cycle stage, whereby the diestrus phase was characterized by the predominance of leukocytes [40]. The goal was to sacrifice female animals during the diestrus phase of the estrous cycle to reduce potential variability due to hormonal cycle.

2.3.3. Ballistic Labeling Technique

Methodology for the ballistic labeling technique was initially described by Seabold et al. [41] and was adapted for use in our laboratory by Roscoe et al. [30]; a protocol that was further refined by Li et al. [42].

In brief, the DiI/Tungsten bead tubing was created by dissolving polyvinylpyrrolidone (PVP; 100 mg) in ddH$_2$O (10 mL). Tefzel tubing (Bio-Rad, Hercules, CA, USA) was filled with the PVP solution for 20 min and then expelled. DiOlistic cartridges were prepared by dissolving tungsten beads (170 mg; Bio-Rad) with 99.5% methylene chloride (250 µL; Sigma-Aldrich, St. Louis, MO, USA); the tungsten bead suspension was vortexed to mix thoroughly. Additionally, DiIC18(3) dye (6 mg; Invitrogen, Carlsbad, CA, USA) was dissolved in 99.5% methylene chloride (300 µL) and vortexed. The tungsten bead suspension was pipetted onto a glass slide and allowed to dry. After pipetting the DiIC18(3) dye solution on top of the tungsten bead suspension, the two layers were mixed; the tungsten bead suspension/DiIC18(3) dye mixture was split into two 1.5 mL centrifuge tubes filled with ddH$_2$O and sonicated. The homogenized mixture in the 1.5 mL centrifuge tubes was combined into a 15 mL conical tube, further sonicated, drawn into the PVP-coated Tefzel tubing, and fed into the tubing preparation station (Bio-Rad). After the PVP-coated Tefzel tubing with the homogenous tungsten bead suspension/DiIC18(3) dye mixture (i.e., DiOlistic cartridge) rotated for one minute, all water was removed. Rotating continued for an additional 30 min under nitrogen gas (0.5 L per minute). Once dried, the DiOlistic cartridges were cut into 13 mm lengths and stored in the dark until subsequent use.

HIV-1 Tg and control animals were deeply anesthetized using 5% sevoflurane (Abbot Laboratories, North Chicago, IL, USA) and transcardially perfused. The rat brain was removed, postfixed in 4% paraformaldehyde for 10 min and cut coronally (500 µm) using a rat brain matrix (ASI Instruments, Warren, MI, USA). Coronal slices were placed into a 24 well-plate with 100 mM phosphate-buffered saline (PBS; 1 mM). Before ballistic labeling, the PBS was removed from the well-plate.

Ballistic labeling was conducted using the Helios gene gun (Bio-Rad), which was loaded with previously prepared DiOlistic cartridges. A piece of filter paper was placed be-
between the two mesh screens on the Helios gene gun. For ballistic delivery, helium gas flow was adjusted to 90 pounds per square inch and the applicator was placed approximately 2.5 cm away from the brain slices. After ballistic delivery, slices were washed three times in 100 mM PBS and stored in the dark at 4 °C for three hours. Brain slices were transferred onto a glass slide, mounted using Pro-Long Gold Antifade (Invitrogen), and cover-slipped (#1 cover slip; Thermo Fisher Scientific, Waltham, MA, USA). Slides were stored in the dark at 4 °C until imaging.

2.3.4. Confocal Imaging of Pyramidal Neurons

Pyramidal neurons from layers II-III of the mPFC, located approximately 3.7 mm to 2.2 mm anterior to Bregma [43], were imaged for analysis (Figure 2). Z-stack images (60× oil objective (n.a. = 1.4) with Z-plane interval of 0.15 μm) of three pyramidal neurons from each animal were obtained using a Nikon TE-200E confocal microscope and Nikon’s EZ-C1 software (version 3.81b). The DiI fluorophore was excited using a green helium-neon laser with an emission of 543 nm.

![Figure 2. Representative images of DiOlistically labeled pyramidal neurons in layers II-III of the medial prefrontal cortex (mPFC) in control (A,B) and HIV-1 transgenic Tg; (C,D) animals at postnatal day (PD) 30 (A,C) and PD 180 (B,D).](image)

2.3.5. Neuronal Analysis and Spine Quantification

Neuronal morphology and dendritic spines were analyzed using sophisticated neuronal reconstruction software (Neurolucida 360, MicroBrightfield, Williston, VT, USA). All neurons were coded prior to analysis. Selection criteria (e.g., continuous dendritic staining, low background/dye clusters), illustrated in Li et al. [42], were used to select one neuron from each animal for analysis. Neurons not meeting the selection criteria were not included in the analysis, yielding the following sample sizes: Control: PD 30, n = 19 (male, n = 9, female, n = 10), PD 60, n = 19 (male, n = 10, female, n = 9), PD 90, n = 18 (male, n = 10, female, n = 8), PD 120, n = 17 (male, n = 9, female, n = 8), PD 150, n = 18 (male, n = 8, female, n = 10), PD 180, n = 20 (male, n = 9, female, n = 11); HIV-1 Tg: PD 30, n = 19 (male, n = 10, female, n = 9), PD 60, n = 19 (male, n = 10, female, n = 9), PD 90, n = 18 (male, n = 8, female, n = 10), PD 120, n = 20 (male, n = 10, female, n = 10), PD 150, n = 19 (male, n = 9, female,
n = 10), PD 180, n = 18 (male, n = 9, female, n = 9). Following selection, the apical dendrite of pyramidal neurons from layers II-III of the mPFC was examined.

Morphological characteristics of pyramidal neurons from layers II-III of the mPFC were examined using three approaches, including apical dendrite length, Sholl analysis [44] and centrifugal branch ordering. The classical Sholl analysis affords an opportunity to examine neuronal arbor complexity by counting the number of dendritic intersections occurring at successive concentric circles placed fixed distances (i.e., 10 µm) from the soma. A centrifugal branch ordering scheme assigned each dendrite with a branch order by counting the number of segments traversed; an assessment of dendritic branching complexity.

The morphology of dendritic spines was characterized by three parameters, including volume (µm³), backbone length (µm), and head diameter (µm). Boundary conditions for each parameter were established using well-accepted previously published results (volume, 0.05 to 0.85 µm³: [45]; backbone length, 0.4 to 4.0 µm: [46, 47]; head diameter, 0 to 1.2 µm: [48]). Dendritic spines recognized by the sophisticated neuronal software, but failing to meet any of the boundary conditions, were excluded from dendritic spine morphological analyses.

2.4. Experiment #2: Neuroinflammatory Markers in the Medial Prefrontal Cortex (mPFC)

Neuroinflammation was assessed in the mPFC of HIV-1 Tg (n = 20; Male, n = 10, Female, n = 10) and control (n = 20; Male, n = 10, Female, n = 10) animals at PD 30 using real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays (ELISA).

2.4.1. Sacrifice

HIV-1 Tg and control animals were humanely euthanized and sacrificed by rapid decapitation. Brains were removed and the frontal cortex was dissected and stored at −80 °C until being utilized for either RT-PCR or ELISA.

2.4.2. Real-Time Polymerase Chain Reaction (RT-PCR)

The RNeasy FFPE kit (QIAGEN, Germantown, MD, USA) was utilized to isolate the total RNA from 30 mg of mPFC tissue. Using the Invitrogen (Carlsbad, CA, USA) Cloned AMV First-Strand cDNA Synthesis Kit, one µg of total RNA from each sample was converted into cDNA. Details regarding the cDNA synthesis reaction mixture are available in McLaurin et al. [18].

Subsequently, three neuroinflammatory markers, including IL-1β, IL-6, and TNF-α were quantified using real-time PCR and the SsoAdvanced Universal SYBR Green Supermix Kit (BIO-RAD, Hercules, CA, USA). β-actin was used as an internal control. Methodological details are available in McLaurin et al. [18]. Animals failing to reach threshold after 40 cycles were considered to have undetectable gene expression and accordingly these censored data were not included in the figures or statistical analysis, yielding Control, n = 20, male, n = 10, female, n = 10, and HIV-1 Tg n = 13–19, male, n = 6–10, female, n = 7–9, dependent upon gene. Data were analyzed using Intuitive Opticon Monitor TM software.

2.4.3. Enzyme-Linked Immunosorbent Assay (ELISA)

Brain tissue lysates were prepared from 12–54 mg of fresh frozen PFC tissue. RIPA Lysis and Extraction Buffer (1×, Thermo Scientific, Waltham, MA, USA) were added to extract protein from the brain tissue. Tissue was disrupted using hand sonication. Lysates were subsequently centrifuged (14,400 rpm at 4 °C for 20 min) and the supernatant was collected. A commercial ELISA kit was utilized to evaluate levels of IL-1β (R&D Systems, Inc., Minneapolis, MN, USA), the cytokine with the highest levels of expression in RT-PCR. ELISA was analyzed in duplicate.
2.5. Statistical Analysis

Analysis of variance (ANOVA) and regression techniques ((SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC, USA; SPSS Statistics 27, IBM Corp., Somer, NY, USA; GraphPad Software, Inc., La Jolla, CA, USA) were utilized for the statistical analysis of all data. Statistical significance was set at an alpha criterion of \( p \leq 0.05 \).

Multiple dependent measures were utilized to evaluate the impact of chronic HIV-1 viral protein exposure, biological sex, and/or age on regressive processes, including dendrite and synaptic pruning. To evaluate the progression of neuronal arbor complexity, area under the Sholl curve was derived from the classic Sholl intersection profile for each animal at every age. A mixed-model ANOVA with a compound symmetry covariance structure (PROC MIXED; SAS/STAT Software 9.4) was utilized to statistically analyze the area under the Sholl curve. The classic Sholl intersection profile was analyzed using a mixed-model ANOVA with a variance components covariance structure (PROC MIXED; SAS/STAT Software 9.4), as recommended by Wilson et al. [49]. The total number of dendritic branches, an index of dendritic branching complexity, and dendritic spines, a measure of excitatory synapses, were evaluated using a generalized linear mixed-effects model with a Poisson distribution and unstructured covariance structure (PROC GLIMMIX; SAS/STAT Software 9.4). Complementary regression techniques (GraphPad Software, Inc.) were also used to assess the development of apical dendrite length, neuronal arbor complexity, dendritic branching complexity, and excitatory synapses.

Synaptic connectivity was assessed by evaluating the number of dendritic spines between each successive radii. Three measures of dendritic spine morphology, including dendritic spine volume, backbone length, and head diameter, were analyzed by examining the number of dendritic spines within each bin. A generalized linear mixed-effects model with a Poisson distribution and an unstructured covariance pattern was conducted using PROC GLIMMIX (SAS/STAT Software 9.4) for both synaptic connectivity and dendritic spine morphological parameters. The statistical analyses for dendritic spine backbone length were conducted for bins from 0.4 µm to 2.0 µm. Furthermore, the statistical analyses for dendritic spine head diameter were conducted for dendritic spines with a head diameter greater than 0.01 µm. Radii and bin served as within-subjects factors, as appropriate, whereas genotype (HIV-1 Tg vs. Control), biological sex (Male vs. Female), and age (Synaptic Connectivity: PD 30 vs. PD 180; Dendritic Spine Morphology: PD 30, PD 60, PD 90, PD 120, PD 150, PD 180) served as between-subjects factors.

Putative neuroinflammatory markers were examined using two complementary measures, including RT-PCR and ELISA. For RT-PCR, gene expression was investigated using \( \Delta CT \), which was calculated by subtracting the gene of interest from the internal control (i.e., \( \beta \)-actin). \( \Delta CT \) was analyzed independently for each neuroinflammatory marker using a mixed-model ANOVA (PROC MIXED; SAS/STAT Software 9.4). Interactions were further evaluated using simple effects in the context of the overall analysis. For ELISA, the concentration was averaged across the two duplicates to account for the nested data structure and analyzed using a mixed-model ANOVA (SPSS Statistics 27). Genotype (HIV-1 Tg vs. Control) and biological sex (Male vs. Female) served as between-subjects factors.

3. Results

3.1. Experiment #1: Neurodevelopmental Alterations in the Medial Prefrontal Cortex (mPFC)

3.1.1. Presence of HIV-1 Viral Proteins Results in Abnormal Development and Patterning of Dendritic Branches

HIV-1 Tg animals displayed prominent alterations in the development and patterning of apical dendrites in pyramidal neurons in layers II-III of the mPFC, evidenced by three complementary measures of neuronal morphology (i.e., Dendrite Length, Figure 3A; Sholl Analysis, Figure 3B; Dendritic Branching, Figure 3C).
Figure 3. Chronic HIV-1 viral protein exposure alters neuronal development in pyramidal neurons from layers II-III of the medial prefrontal cortex, evidenced by measurements of apical dendrite length (A), Sholl analysis (B) and dendritic branching (C). To evaluate the progression of neuronal arbor complexity, the area under the Sholl curve was derived from the classic Sholl intersection profile. HIV-1 Tg animals exhibited a linear increase in dendrite length, the area under the Sholl curve, and the total number of dendritic branches across development; a developmental trajectory that was in sharp contrast to observations in control animals. Data are illustrated as a function of genotype (Control vs. HIV-1 Tg) and age (X ± 95% confidence intervals).

A differential progression, dependent upon genotype, was observed in both apical dendrite length (Figure 3A) and the area under the Sholl curve (Figure 3B; Genotype × Age interaction, F(5, 200) = 2.6, p ≤ 0.03). Specifically, in control animals, apical dendrite length and the classical Sholl analysis revealed initial neuronal arbor elaboration (i.e., PD 30) followed by dendritic pruning during adolescence (i.e., PD 60) and the stabilization of the neuronal arbor (i.e., PD 90–180; Best Fit: Segmental Linear Regression, R^2 ≥ 0.84 and R^2 ≥ 0.87 for apical dendrite length and area under the Sholl curve, respectively). In HIV-1 Tg animals, however, a linear increase in both apical dendrite length and neuronal arbor complexity was observed across development (Best Fit: First-Order Polynomial, R^2 ≥ 0.71 and R^2 ≥ 0.83 for apical dendrite length and area under the Sholl curve, respectively). Critically, with regards to the Sholl analysis, examination of the Sholl intersection profile revealed consistent observations (Supplementary Figure S2; Genotype × Age × Radius interaction, F(5, 5352) = 3.1, p ≤ 0.01).

Furthermore, profound alterations in the branching complexity of dendrites were observed in HIV-1 Tg animals relative to controls (Figure 3C; Genotype × Age interaction, F(5, 200) = 2.4, p ≤ 0.04)). HIV-1 Tg animals exhibited a progressive increase in the total number of dendritic branches throughout development (Best Fit: First-Order Polynomial, R^2 ≥ 0.96); a sharp contrast to the stable number of total dendritic branches observed in control animals. Taken together, HIV-1 Tg animals exhibited enhanced neuronal arbor and branching complexity across development relative to control animals.

3.1.2. HIV-1 Tg Animals Exhibited a Linear Increase in the Number of Dendritic Spines, a Proxy for the Number of Excitatory Synapses, across Development

Given that dendritic spines typically contain a single type 1 asymmetric synapse, the total number of dendritic spines may serve as a proxy for the number of excitatory synapses (for review, [50]). A differential progression, dependent upon genotype, was observed in the total number of dendritic spines across development (Figure 4; Genotype × Age Interaction, F(5, 200) = 9.9, p ≤ 0.001). Specifically, control rats, independent of biological sex, exhibited an initial overproduction of dendritic spines (i.e., PD 30) followed by pruning during adolescence (i.e., PD 60) and the stabilization of dendritic spines during adulthood (i.e., PD 90–180; Best Fit: Segmental Linear Regression, R^2 ≥ 0.87). In sharp contrast, HIV-1 Tg animals exhibited a linear increase in the number of dendritic spines across development (Best Fit: First-Order Polynomial, R^2 ≥ 0.92). Thus, independent of biological sex, presence of the HIV-1 transgene alters synaptogenesis, including the establishment, maintenance, and elimination of synapses.
3.1.2. HIV-1 Tg Animals Exhibited a Linear Increase in the Number of Dendritic Spines, Across Development

HIV-1 Tg animals exhibited a prominent rightward shift in the distribution of dendritic spines along the apical dendrite relative to control animals. At PD 30, PD 60, and PD 90 HIV-1 Tg animals exhibited a prominent population of dendritic spines on pyramidal neurons from layers II-III of the medial prefrontal cortex are illustrated as a function of genotype (Control vs. HIV-1 Tg) and radii at PD 30 (B) and PD 180 (C). HIV-1 Tg animals displayed an increased relative frequency of dendritic spines on more distal dendrites relative to control animals at both PD 30 and PD 180; albeit the magnitude of the rightward shift increased with age.

3.1.3. HIV-1 Tg Animals Exhibited a Prominent Rightward Shift in the Distribution of Dendritic Spines Along the Apical Dendrite Relative to Control Animals

HIV-1 Tg animals exhibited a prominent rightward shift in the distribution of dendritic spines along the apical dendrite relative to control animals (Figure 4B,C; Genotype × Age × Radii Interaction, F(1, 1816) = 40.3, p ≤ 0.001). Specifically, independent of age, HIV-1 Tg animals displayed a preponderance of dendritic spines on more distal dendrites relative to control animals; albeit a more pronounced rightward shift was observed at PD 180. Furthermore, it is notable that the factor of biological sex also influenced the magnitude, but not the pattern, of the distributional shift (Genotype × Age × Sex × Radii Interaction, F(1, 1816) = 154.6, p ≤ 0.001). Results support, therefore, a developmental decrease in synaptic connectivity in HIV-1 Tg animals.

3.1.4. HIV-1 Tg Rats Exhibited Progressive Dendritic Spine Dysmorphology, Evidenced by Developmental Alterations in Dendritic Spine Volume, Backbone Length, and Head Diameter

HIV-1 Tg animals exhibited a progressive decrease in dendritic spine volume throughout development; a sharp contrast to the age-related increase observed in control animals (Figure 5A; Best Fit: First-Order Polynomial, R² ≥ 0.54). Furthermore, examination of the distribution of dendritic spines (Figure 5B) confirmed the differential development of dendritic spine volume (Genotype × Age × Bin Interaction, F(80, 3200) = 3.2, p ≤ 0.001). Specifically, at PD 30, PD 60, and PD 90 HIV-1 Tg animals exhibited a prominent population shift towards increased dendritic spine volume relative to control animals. At PD 120, PD 150, and PD 180, however, a profound population shift towards decreased dendritic spine...
volume was observed in HIV-1 Tg, relative to control, animals. The factor of biological sex altered the magnitude (Genotype × Sex × Age × Bin Interaction, $F(80, 3200) = 1.7, p \leq 0.001$), but not the pattern, of the distributional shift.

![Graph A](image)

**Figure 5.** HIV-1 Tg animals exhibited a progressive decrease in dendritic spine volume. (A) The 75th percentile of dendritic spine volume was derived from the distribution of dendritic spines (X ± 95% confidence intervals). HIV-1 Tg animals exhibited a linear decrease in dendritic spine volume across development, whereas control animals displayed an age-related linear increase in dendritic spine volume. (B) Examination of the distribution of dendritic spine volume in HIV-1 Tg and control animals as a function of age confirmed the observations inferred from the 75th percentile of dendritic spine volume.

Examination of the distribution of dendritic spine backbone length (Figure 6A; Genotype × Age × Bin Interaction, $F(80, 3200) = 14.8, p \leq 0.001$) and head diameter (Figure 6B; $F(55, 2200) = 28.3, p \leq 0.001$) afford additional support for progressive dendritic spine dysmorphology in HIV-1 Tg animals. Specifically, at PD 30, PD 60, and PD 90 HIV-1 Tg animals exhibited a prominent population shift towards shorter dendritic spines with increased head diameter relative to control animals. At PD 120, PD 150, and PD 180, however, a profound population shift towards longer dendritic spines with decreased head diameter was observed in HIV-1 Tg, relative to control, animals.
Figure 6. Dendritic spine dysmorphology in pyramidal neurons from layers II-III of the medial prefrontal cortex in the HIV-1 Tg rat was further characterized by a developmental increase in dendritic spine backbone length (A) and progressive decrease in dendritic spine head diameter (B) relative to control animals. Data are illustrated as relative frequencies.

3.2. Experiment #2: Neuroinflammatory Markers in the Medial Prefrontal Cortex

There Is No Compelling Evidence for Neuroinflammation in the mPFC of HIV-1 Tg Rats during Early Development

Three putative neuroinflammatory markers, including IL-1β, IL-6, and TNF-α, were examined at PD 30 using RT-PCR. Overall, independent of genotype and/or biological sex, low levels of gene expression were observed, evidenced by cycle threshold (CT) values ranging from 26.1 to 40 for IL-1β, from 31.3 to 40 for IL-6 and from 25.7 to 40 for TNF-α. Data are presented as ΔCT values (i.e., Internal Control (β-actin)–Gene of Interest), whereby higher ΔCT values indicate lower gene expression and lower ΔCT values represent higher gene expression. With regards to IL-1β, a higher level of gene expression was observed in female animals, independent of genotype, relative to male animals (Figure 7A; Main Effect: Sex, F(1, 35) = 5.5, p ≤ 0.03). Examination of IL-6 revealed a statistically significant
main effect of genotype (Figure 7B; $F(1, 29) = 6.2, p \leq 0.02$), whereby HIV-1 Tg animals, independent of biological sex, exhibited a lower level of gene expression relative to control animals. For TNF-α, gene expression was dependent upon an interaction between genotype and biological sex (Figure 7C; $F(1, 33) = 5.6, p \leq 0.02$); an interaction resulting from decreased gene expression in HIV-1 Tg male animals relative to control male rats ($t(33) = -2.2, p \leq 0.03$).

Given that the highest levels of gene expression were observed for IL-1β, ELISA was subsequently performed to evaluate IL-1β at the protein level. There were no statistically significant main effects and/or interactions for the concentration of IL-1β ($p > 0.05$; Supplementary Figure S3). Thus, collectively, there is no compelling evidence for neuroinflammation in the mPFC of HIV-1 Tg rats.

### 4. Discussion

Constitutive expression of HIV-1 viral proteins induces prominent neurodevelopmental alterations and progressive synaptodendritic dysfunction, independent of biological sex, in pyramidal neurons from layers II-III of the mPFC (Figure 8). Profound neurodevelopmental alterations in the HIV-1 Tg rat were evidenced by prominent deficits in dendritic and synaptic pruning, processes that are a hallmark of adolescent brain maturation (for review, [51]). Progressive synaptodendritic dysfunction was evidenced by an examination of the continuous morphological parameters of dendritic spines. Specifically, HIV-1 Tg animals exhibited an age-related population shift towards dendritic spines with decreased volume, increased backbone length, and decreased head diameter; parameters associated with a more immature dendritic spine phenotype. Based on an examination of three putative neuroinflammatory markers early in development (i.e., PD 30), there was no compelling evidence for neuroinflammation in the mPFC of HIV-1 Tg rats. Collectively, progressive neuronal and dendritic spine dysmorphology herald synaptodendritic dysfunction as a key neural mechanism underlying chronic neurocognitive impairments in pALHIV.
Figure 8. The prominent age-related changes in pyramidal neurons from layers II-III of the medial prefrontal cortex are illustrated at postnatal day (PD) 30 and PD 180 for control (A) and HIV-1 Tg (B) animals. (A) At PD 30, control animals exhibited exuberant neurite and dendritic spine growth; excessive growth that was pruned during adolescence and maintained through adulthood. Furthermore, dendritic spines in control animals matured, evidenced by a progressive increase in dendritic spine volume, an age-related decrease in dendritic spine backbone length, and a developmental increase in dendritic spine head diameter; morphological parameters which are consistent with a ‘mushroom’ dendritic spine phenotype. (B) HIV-1 Tg animals exhibited abnormal neuronal and dendritic spine development. Specifically, HIV-1 Tg animals displayed a linear increase in neurite growth and dendritic spines across development, supporting aberrant dendritic and synaptic pruning. Additionally, dendritic spines in HIV-1 Tg animals regressed across development, evidenced by an age-related decrease in dendritic spine volume, a developmental increase in dendritic spine backbone length, and a progressive decrease in dendritic spine head diameter; morphological parameters which are consistent with a ‘thin’ dendritic spine phenotype.

In the PFC, neurite [13] and synaptic [11,52] pruning are a hallmark of adolescent neurodevelopment [51]. Observations in control animals, independent of biological sex, corroborate these previous findings. In HIV-1 Tg animals, however, regressive processes were profoundly altered, evidenced by a linear increase in indices of apical dendrite length, neuronal arbor complexity, dendritic branching complexity, and excitatory synapses throughout development; alterations which may be due, at least in part, to microglial dysfunction. Specifically, early in the course of infection, HIV-1-infected monocytes migrate across the blood-brain barrier infiltrating the brain and infecting microglia [53,54]. Following chronic HIV-1 viral protein exposure, microglia serve as a viral reservoir for HIV-1 in the brain [36,54,55] supporting a cell type that may underlie aberrant neurite and synaptic pruning.

Under homeostatic conditions, microglia exhibit a ramified morphology with small somas and highly branched processes supporting constant environmental surveillance [56,57]; surveillance which is uniquely targeted to synaptic structures, including dendritic spines [58,59]. During brain development, microglia are involved in the phagocytic and/or trogocytotic elimination of neurites (e.g., [60–62]) and synapses (e.g., [63–65]). Proteins and receptors expressed by microglia (e.g., complement component 1q (C1q) [66]; complement receptor 3 (CR3) [67]; CX3C chemokine receptor 1 (Cx3cr1) [68,69]), have been implicated...
as potential mechanisms underlying microglia-mediated neurite and pre- and postsynaptic engulfment [61–64,70]. Specifically, genetic deletion of C1q [70], CR3 [64], or Cx3cr1 [61,63] precludes neurite and/or synaptic pruning. Furthermore, increasing or decreasing the activity level of the complement system results in either excessive or impaired neurite pruning, respectively [62]. Critically, the complement system and Cx3cr1 are dysregulated by HIV-1 viral proteins [71,72] and associated with neuronal injury in HIV-1 seropositive individuals [73]; alterations that support a convergent mechanism underlying the prominent alterations in regressive processes observed in the HIV-1 Tg rat.

After synaptic pruning, the remaining synapses are functionally strengthened and elaborated to aid in the formation of mature neural circuits. The PFC is highly connected with other cortical and subcortical regions making it well suited to serve as a central hub, integrating and relaying information throughout the brain (for review, [74]). In addition to excitatory glutamatergic and inhibitory gamma-aminobutyric acid afferents, the PFC is densely innervated by dopaminergic, noradrenergic, and serotonergic projections from multiple brain regions (i.e., ventral tegmental area, locus coeruleus, and dorsal and median raphe nuclei, respectively [14]). The vast majority of afferent projections synapse on dendritic spines of pyramidal neurons [75] supporting their fundamental role in neural circuits. Therefore, two complementary approaches were utilized to establish the progression of dendritic spine alterations in the HIV-1 Tg rat, including an examination of their distribution and an evaluation of their morphological parameters.

Independent of age (i.e., PD 30 or PD 180), HIV-1 Tg animals exhibited a prominent rightward shift in the distribution of dendritic spines along the apical dendrite relative to controls; an observation that supports an alteration in synaptic connectivity. Architecturally, the PFC is organized in a laminar fashion from superficial (i.e., Layer I) to deep (i.e., Layer VI [14]); pyramidal neurons from layers II-III of the mPFC extend superficially into layer I. Dopaminergic, noradrenergic, and serotonergic receptors are abundantly expressed in layers II-III, but not layer I, of the mPFC [76]. In HIV-1 Tg rats, therefore, the preponderance of dendritic spines on distal dendrites, which extend into layer I, supports alterations in neurotransmitter innervation and synaptic connectivity. Indeed, neurotransmitter systems, including the dopamine (for review, [77]), norepinephrine (e.g., [78]) and serotonin (e.g., [79,80]) systems, are dysregulated by HIV-1 viral protein exposure. Furthermore, the magnitude of the rightward shift in the distribution of dendritic spines along the apical dendrite progresses with age in HIV-1 Tg animals, supporting an age-related loss in neurotransmitter innervation and synaptic connectivity.

With regards to the morphological parameters of dendritic spines, a discrete classification system, consisting of four categories (i.e., filopodia, mushroom, stubby, thin), has been traditionally utilized to characterize dendritic spines [81]. Mushroom spines, which are considered the most mature morphology (for review, [50]), contain a large dendritic spine head and small dendritic spine neck [81]. Stable mushroom spines form strong synaptic connections, evidenced, at least in part, by their large postsynaptic densities and high α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to N-methyl-D-aspartate (NMDA) ratios [30]. Dendritic spines classified as either stubby (i.e., absence of a dendritic spine neck) or thin (i.e., long, thin dendritic spine neck and a smaller dendritic spine head), however, are considered immature dendritic spines. Although both stubby and thin spines contain synaptic structures, they have lower AMPA to NMDA ratios and are more transient [50]. Filopodia-like structures, which lack a clear type 1 synapse [82], are regarded as the most immature type of dendritic protrusion [50]. Based on these categorizations, the predominant dendritic spine morphology in HIV-1 Tg animals regresses from a mature ‘mushroom’ phenotype to an immature ‘thin’ phenotype across time. More recently, however, it has been recognized that spine morphology is more accurately assessed by continuous numerical measures (e.g., [46,47]), as in the current study.

Indeed, the examination of continuous dendritic spine morphological parameters adds additional credence for progressive synaptodendritic dysfunction in the HIV-1 Tg rat. Continuous morphological measurements have revealed the tight coupling between
dendritic spine structure and synaptic function [46,83–85]. Specifically, increased total dendritic spine volume is strongly associated with increased area of the postsynaptic density (PSD; $r = 0.51$ to 0.88; [46,83,84]). Furthermore, the dendritic spine head is positively correlated with both the area of the PSD ($r = 0.88$; [46,84]) and the number of synaptic vesicles ($r = 0.92$; [84]). In sharp contrast, dendritic spine neck length is negatively correlated with synaptic efficacy ($r = -0.72$; [85]). HIV-1 Tg animals exhibited an age-related decrease in dendritic spine volume and head diameter, as well as an age-related increase in backbone length; a population shift supporting a developmental decrease in synaptic function.

Despite the power of continuous dendritic spine morphological measurements, a few caveats must be acknowledged. First, electrophysiological recordings of pyramidal neurons in the mPFC were not conducted in the present study. However, recent observations of increased intrinsic excitability in pyramidal neurons from layers II-III of the mPFC following HIV-1 Tat expression [86] support alterations in the neural circuitry evaluated herein. Second, there was also an absence of biochemical analyses, including measurements of PSD-95 and/or SAP102, to measure synaptic function. However, decreased expression of PSD-95 has been previously reported following exposure to HIV-1 Tat [87]; inferences drawn from the rigorous morphological assessment of dendritic spines, therefore, are consistent with previous findings.

Notably, the neurodevelopmental alterations in regressive processes and synaptic function occurred in the absence of any significant neuroinflammation early in development; findings which are consistent with our current knowledge of the clinical syndrome in the post-cART era. Inflammatory markers measured in the periphery (e.g., blood samples) of children perinatally infected with HIV-1 are significantly elevated relative to controls (e.g., [88–90]). Peripheral inflammation, however, is distinct from neuroinflammation (e.g., measurements from cerebrospinal fluid (CSF)) evidenced by limited concordance between plasma and CSF immunological markers in children perinatally infected with HIV-1 [90]. Indeed, in the CSF of HIV-1 seropositive children, multiple proinflammatory markers are undetectable [91].

In conclusion, constitutive expression of HIV-1 viral proteins induced profound neurodevelopmental alterations and progressive synaptodendritic dysfunction, independent of biological sex, in pyramidal neurons from layers II-III of the mPFC. Neurodevelopmental alterations in the HIV-1 Tg rat were characterized by aberrant neurite and synaptic pruning. Progressive synaptodendritic dysfunction was evidenced by an age-related decrease in synaptic connectivity and a population shift towards a more immature dendritic spine phenotype. Collectively, progressive neuronal and dendritic spine dysmorphology herald synaptodendritic dysfunction as a key neural mechanism underlying chronic neurocognitive impairments in pALHIV.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/cells10113037/s1, Figure S1: Body Weight, Figure S2: Sholl Intersection Profile, Figure S3: IL-1β ELISA.

**Author Contributions:** R.M.B. and C.F.M. designed the study. K.A.M., H.L., R.M.B., and C.F.M. planned the study and collected the data. K.A.M., H.L., and C.F.M. analyzed the data. K.A.M., R.M.B., and C.F.M. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported in part by grants from NIH (National Institute on Drug Abuse, DA013137; National Institute of Child Health and Human Development, HD043680; National Institute of Mental Health, MH106392; National Institute of Neurological Disorders and Stroke, NS100624) and the interdisciplinary research training program supported by the University of South Carolina Behavioral-Biomedical Interface Program.

**Institutional Review Board Statement:** AAALAC-accredited facilities and guidelines established in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health were utilized for the maintenance of HIV-1 Tg and control animals. The Institutional Animal Care and
Use Committee (IACUC) at the University of South Carolina approved (25 March 2019) the project protocol (Federal Assurance, #D16-00028).

Informed Consent Statement: Not applicable.

Data Availability Statement: All relevant data are within the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Oleske, J.; Minnefor, A.; Cooper, R.; Thomas, K.; Cruz, A.D.; Adhieh, H.; Guerrero, I.; Joshi, V.V.; Desposito, F. Immune deficiency syndrome in children. JAMA 1983, 249, 2345–2349. [CrossRef]
2. Rubinstein, A.; Sicklick, M.; Gupta, A.; Bernstein, L.; Klein, N.; Rubinstein, E.; Spigland, I.; Fruchter, L.; Litman, N.; Lee, H.; et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA 1983, 249, 2350–2356. [CrossRef]
3. Dunn, D.; Woodburn, P.; Duong, T.; Peto, J.; Phillips, A.; Gibb, D.; Porter, K. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J. Infect. Dis. 2008, 197, 398–404. [CrossRef] [PubMed]
4. Viani, R.M.; Araneta, M.R.G.; Deville, J.G.; Spector, S.A. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. 2004, 39, 725–731. [CrossRef]
5. Palladino, C.; Climent, F.J.; De José, M.I.; De Ory, S.J.; Bellon, J.; Guillén, S.; Gurbindo, M.D.; González-Tomé, I.; Mellado, M.J.; Pérez, J.M.; et al. Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009. Pediatr. Infect. Dis. J. 2011, 30, 495–500. [CrossRef] [PubMed]
6. Adolescent HIV Prevention. Available online: https://data.unicef.org/topic/hiv/aids/adolescents-young-people/ (accessed on 26 August 2021).
7. Laughton, B.; Cornell, M.; Boivin, M.; Van Rie, A. Neurodevelopment in perinatally HIV-infected children: A concern for adolescence. J. Int. AIDS Soc. 2013, 16, 18603. [CrossRef]
8. Stiles, J.; Jernigan, T.L. The basics of brain development. Neuropsychol. Rev. 2010, 20, 327–348. [CrossRef] [PubMed]
9. Hamburger, V.; Levi-Montalcini, R. Proliferation, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions. J. Exp. Zool. 1949, 111, 457–501. [CrossRef]
10. Heumann, D.; Leuba, G.; Rabinovicz, T. Postnatal development of the mouse cerebral neocortex. IV. Evolution of the total cortical volume, of the population of neurons and glia cells. J. Hirnforsch. 1978, 19, 385–393.
11. Huttenlocher, P.R. Synaptic density in human frontal cortex—Developmental changes and effects of aging. J. Comp. Neurol. 1979, 163, 195–205.
12. Petanjek, Z.; Judaš, M.; Šimić, G.; Rašin, M.R.; Uylings, H.B.M.; Rakic, P.; Kostović, I. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc. Natl. Acad. Sci. USA 2011, 108, 13281–13286. [CrossRef]
13. Cressman, V.L.; Balaban, J.; Steinfeld, S.; Shemyakin, A.; Graham, P.; Parisot, N.; Moore, H. Prefrontal cortical inputs to the basal amygdala undergo pruning during late adolescence in the rat. J. Comp. Neurol. 2010, 518, 2693–2709. [CrossRef] [PubMed]
14. Fuster, J.M. The Prefrontal Cortex, 4th ed.; Elsevier Academic Press: London, UK, 2008.
15. Van Eden, C.G.; Uylings, H.B.M. Cytoarchitectonic development of the prefrontal cortex in the rat. J. Comp. Neurol. 1985, 241, 253–267. [CrossRef]
16. Eayrs, J.T.; Goodhead, B. Postnatal development of the cerebral cortex in the rat. J. Anat. 1959, 93, 385–402.
17. McLaurin, K.A.; Booze, R.M.; Mactutus, C.F. Progression of temporal processing deficits in the HIV-1 transgenic rat. Sci. Rep. 2016, 6, 32831. [CrossRef] [PubMed]
18. McLaurin, K.A.; Li, H.; Booze, R.M.; Mactutus, C.F. Disruption of timing: NeuroHIV progression in the post-cART era. Sci. Rep. 2019, 9, 827. [CrossRef] [PubMed]
19. Phillips, N.; Amos, T.; Kuo, C.; Hoare, J.; Ipser, J.; Thomas, K.G.F.; Stein, D. HIV-associated cognitive impairment in perinatally infected children: A meta-analysis. Pediatrics 2016, 138, e20160893. [CrossRef]
20. Narayanan, Y.; Garvey, L.J.; Ashby, J.; Foster, C.J.; Fidler, S.; Winston, A. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1–infected adolescents surviving into adulthood. J. Acquir. Immune Defic. Syndr. 2010, 55, 134–136. [CrossRef]
21. Koekkoek, S.; de Sonneville, L.M.; Wolfs, T.F.; Licht, R.; Geelen, S.P. Neurocognitive function profile in HIV-infected school-age children. Eur. J. Paediatr. Neurol. 2008, 12, 290–297. [CrossRef] [PubMed]
22. Nagarajan, R.; Sarma, M.K.; Thomas, M.A.; Chang, L.; Natha, U.; Wright, M.; Hayes, J.; Nielsen-Saines, K.; Michalik, D.E.; Deville, J.; et al. Neuropsychological function and cerebral metabolites in HIV-infected youth. J. Neuroimmune Pharmacol. 2012, 7, 981–990. [CrossRef]
23. Ezeamama, A.E.; Kizza, F.N.; Zalwango, S.K.; Nkwata, A.K.; Zhang, M.; Rivera, M.L.; Whalen, C.C. Perinatal HIV status and executive function during school-age and adolescence: A comparative study of long-term cognitive capacity among children from a high HIV prevalence setting. Medicine (Baltimore) 2016, 95, e3438. [CrossRef]
24. Kraemer, H.C.; Yesavage, J.A.; Taylor, J.L.; Kupfer, D. How can we learn about developmental processes from cross-sectional studies, or can we? Am. J. Psychiatry 2000, 157, 163–171. [CrossRef]

25. Van den Hof, M.; Ter Haar, A.M.; Scherpvler, H.J.; van der Lee, J.H.; Reiss, P.; Wit, F.W.; Pajkrt, D. Neurocognitive development in perinatally human immunodeficiency virus-infected adolescents on long-term treatment, compared to healthy matched controls: A longitudinal study. Clin. Infect. Dis. 2020, 70, 1364–1371. [CrossRef]

26. Casas, R.; Muthusamy, S.; Wakin, P.G.; Sinharay, S.; Lentz, M.R.; Reid, W.C.; Hammoud, D.A. MR brain volumetric measurements are predictive of neurobehavioral impairment in the HIV-1 transgenic rat. Neuroimage Clin. 2018, 17, 699–666. [CrossRef]

27. Gelman, B.B.; Nguyen, T.P. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: Proteomic analysis of human synaptosomes. J. Neuroimmunol. Pharmacol. 2010, 5, 92–102. [CrossRef]

28. Desplats, P.; Dumaop, W.; Smith, D.; Adame, A.; Everall, I.; Letendre, S.; Ellis, R.; Cherney, M.; Grant, I.; Masliah, E. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013, 80, 1415–1423. [CrossRef]

29. Fitting, S.; Ignatowska-Jankowska, B.M.; Bull, C.; Skoff, R.P.; Lichtman, A.H.; Wise, L.E.; Fox, M.A.; Su, J.; Medina, A.E.; Krahe, T.E.; et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol. Psychiatry 2013, 73, 443–453. [CrossRef]

30. Roscoe, R.F.; Mactutus, C.F.; Booze, R.M. HIV-1 Transgenic female rat: Synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J. Neuroimmune Pharmacol. 2014, 9, 642–653. [CrossRef]

31. Mahajan, D.S.; Desiraju, T. Alterations of dendritic branching and spine densities of hippocampal CA3 pyramidal neurons induced by operant conditioning in the phase of brain growth spurt. Exp. Neurol. 1988, 100, 1–15. [CrossRef]

32. Comery, T.A.; Stamosoudis, C.X.; Irwin, S.A.; Greenough, W.T. Increased density of multiple-head dendritic spines on medium-sized spiny neurons of the striatum in rats reared in a complex environment. Neurobiol. Learn. Mem. 1996, 66, 93–96. [CrossRef]

33. Wei, H.; Cheng, K.K.; McCloskey, D.P.; Sheik, A.M.; Malik, M.; Brown, W.T.; Li, X. Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim. Biophys. Acta 2012, 1822, 831–842. [CrossRef]

34. Reid, W.; Sadowska, M.; Menaro, F.; Rao, S.; Foulke, J.; Hayes, N.; Jones, O.; Doodnauth, D.; Davis, H.; Sill, A.; et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl. Acad. Sci. USA 2001, 98, 9271–9276. [CrossRef]

35. Peng, J.; Vigorito, M.; Liu, X.; Zhou, D.; Wu, X.; Chang, S.L. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J. Neuroimmunol. 2010, 218, 94–101. [CrossRef] [PubMed]

36. Li, H.; McLaurin, K.; Iwamoto, J.; Mactutus, C.; Booze, R. Microglial HIV-1 expression: Role in HIV-1 associated neurocognitive disorders. Viruses 2021, 13, 924. [CrossRef]

37. Moran, L.M.; Booze, R.M.; Mactutus, C.F. Time and time again: Temporal processing demands implicate perceptual and gating deficits in the HIV-1 transgenic rat. J. Neuroimmune Pharmacol. 2013, 8, 988–997. [CrossRef]

38. Moran, L.M.; Booze, R.M.; Mactutus, C.F. Modeling deficits in attention, inhibition, and flexibility in HAND. J. Neuroimmune Pharmacol. 2014, 9, 508–521. [CrossRef]

39. Booze, R.M.; Wood, M.L.; Welch, M.; Berry, S.; Mactutus, C.F. Estrous cyclicity and behavioral sensitization in female rats following repeated intravenous cocaine administration. Pharmacol. Biochem. Behav. 1999, 64, 605–610. [CrossRef]

40. Marcondes, F.K.; Bianchi, F.J.; Tanno, A.P. Determination of the estrous cycle phases of rats: Some helpful considerations. Braz. J. Biol. 2002, 62, 609–614. [CrossRef]

41. Seabold, G.K.; Daunais, J.B.; Rau, A.; Grant, K.A.; Alvarez, V.A. DiOLISTIC labeling of neurons from rodent and non-human primate brain slices. J. Vis. Exp. 2010, 41, e2081. [CrossRef] [PubMed]

42. Li, H.; McLaurin, K.A.; Mactutus, C.F.; Booze, R.M. Ballistic labeling of pyramidal neurons in brain slices and in primary cell culture. J. Vis. Exp. 2020, 158, e60989. [CrossRef]

43. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 7th ed.; Elsevier Academic Press: London, UK, 2014.

44. Sholl, D.A. Dendritic organization in the neurons of the visual and motor cortices of the cat. J. Comp. Neurol. 1953, 97, 387–406. [CrossRef]

45. Radley, J.J.; Rocher, A.B.; Rodriguez, A.; Ehlenberger, D.B.; Dammann, M.; McEwen, B.S.; Morrison, J.H.; Wearne, S.L.; Hof, P.R. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex. J. Comp. Neurol. 2008, 507, 1141–1150. [CrossRef] [PubMed]

46. Arellano, J.I.; Benavides-Piccione, R.; DeFelipe, J.; Yuste, R. Ultrastructure of dendritic spines: Correlation between synaptic and spine morphologies. Front. Neurosci. 2007, 1, 131. [CrossRef]

47. Ruszczycki, B.; Szepesi, Z.; Wilczynski, G.M.; Bijata, M.; Kalita, K.; Kaczmarek, L.; Wlodarczyk, J. Sampling issues in quantitative analysis of dendritic spines morphology. BMC Bioinform. 2012, 13, 213. [CrossRef]

48. Konur, S.; Rabinowitz, D.; Fenstermacher, V.L.; Yuste, R. Systematic regulation of spine sizes and densities in pyramidal neurons. J. Neurobiol. 2003, 56, 95–112. [CrossRef]

49. Wilson, M.D.; Sethi, S.; Lein, P.; Keil, K.P. Valid statistical approaches for analyzing Sholl data: Mixed effects versus simple linear models. J. Neurosci. Methods 2017, 279, 33–43. [CrossRef]

50. Berry, K.P.; Nedivi, E. Spine dynamics: Are they all the same? Neuron 2017, 96, 43–55. [CrossRef]

51. Spear, L.P. Adolescent neurodevelopment. J. Adolesc. Health 2013, 52, S7–S13. [CrossRef]

52. Drzewiecki, C.M.; Willing, J.; Juraska, J.M. Synchronous number changes in the medial prefrontal cortex across adolescence in male and female rats: A role for pubertal onset. Synapse 2016, 70, 361–368. [CrossRef] [PubMed]
53. Thompson, K.A.; Cherry, C.L.; Bell, J.E.; McLean, C.A. Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. *Am. J. Pathol.* 2011, 179, 1623–1629. [CrossRef]

54. Ko, A.; Kang, G.; Hattler, J.B.; Galadima, H.; Zhang, J.; Li, Q.; Kim, W.-K. Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy. *J. Neuroimmune Pharmacol.* 2019, 14, 110–119. [CrossRef]

55. Cosenza, M.A.; Zhao, M.-L.; Si, Q.; Lee, S.C. Human brain parenchymal microglia express CD14 and CD 45 and are productively infected by HIV-1 in HIV-1 encephalitis. *Brain Pathol.* 2002, 12, 442–455. [CrossRef]

56. Davalos, D.; Grutzendler, J.; Yang, G.; Kim, J.V.; Zuo, Y.; Jung, S.; Littman, D.R.; Dustin, M.L.; Gan, W.-B. ATP mediates rapid microglial response to local brain injury in vivo. *Nat. Neurosci.* 2005, 8, 752–758. [CrossRef] [PubMed]

57. Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* 2005, 308, 1314–1318. [CrossRef] [PubMed]

58. Wake, H.; Moorhouse, A.J.; Jinno, S.; Kohsaka, S.; Nabekura, J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. *J. Neurosci.* 2009, 29, 3974–3980. [CrossRef]

59. Tremblay, M.E.; Lowery, R.L.; Majewska, A.K. Microglial interactions with synapses are modulated by visual experience. *PLoS Biol.* 2010, 8, e1000527. [CrossRef]

60. Pont-Lezica, L.; Beumer, W.; Colasse, P.; Dreghage, H.; Versnel, M.; Bessis, A. Microglia shape corpus callosum axon tract fasciculation: Functional impact of prenatal inflammation. *Eur. J. Neurosci.* 2014, 39, 1551–1557. [CrossRef]

61. Squarzoni, P.; Oller, G.; Hoeffel, G.; Pont-Lezica, L.; Rostaing, P.; Low, D.; Bessis, A.; Ginhoux, F.; Garel, S. Microglia modulate wiring of the embryonic forebrain. *Cell. Rep.* 2015, 8, 1271–1279. [CrossRef]

62. Lim, T.K.; Ruthazer, E.S. Microglial trogocytosis and the complement system regulate axonal pruning in vivo. *Elife* 2021, 10, e62167. [CrossRef] [PubMed]

63. Paolicelli, R.C.; Bolasco, G.; Pagani, F.; Maggi, L.; Sciami, M.; Panzanelli, P.; Giustetto, M.; Ferreira, T.A.; Guiducci, E.; Dumas, L.; et al. Synaptic pruning by microglia is necessary for normal brain development. *Science* 2011, 333, 1456–1458. [CrossRef]

64. Schafer, D.P.; Lehrman, E.K.; Kautzman, A.G.; Koyama, R.; Mardinly, A.; Yamasaki, R.; Ransohoff, R.M.; Greenberg, M.E.; Barres, B.A.; Stevens, B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron* 2012, 74, 691–705. [CrossRef] [PubMed]

65. Mallya, A.P.; Wang, H.D.; Lee, H.N.; Reuth, A.Y. Microglia pruning of synapses in the prefrontal cortex during adolescence. *Cereb. Cortex* 2019, 29, 1634–1643. [CrossRef] [PubMed]

66. Fonesca, M.I.; Chu, S.H.; Hernandez, M.X.; Fang, M.J.; Modarresi, L.; Selvan, P.; MacGregor, G.R.; Tenner, A.J. Cell-specific deletion of Clqα identifies microglia as the dominant source of C1q in mouse brain. *J. Neuroinflamm.* 2017, 14, 48. [CrossRef]

67. Reichert, F.; Slobovod, U.; Makrancz, C.; Rotshenker, S. Modulation (inhibition and augmentation) of complement receptor-3-mediated myelid phagocytosis. *Neurobiol. Dis.* 2001, 8, 504–512. [CrossRef]

68. Nishiyori, A.; Minami, M.; Ohtani, Y.; Takami, S.; Yamamoto, J.; Kawaguchi, N.; Kume, T.; Akaike, A.; Satoh, M. Localization of fractalkine and CX3CR1 mRNAs in rat brain: Does fractalkine play a role in signaling from neuron to microglia? *FEBS Lett.* 1998, 429, 167–172. [CrossRef]

69. Hughes, P.M.; Botham, M.S.; Frenzelt, S.; Mir, A.; Perry, V.H. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. *Glia* 2002, 37, 314–327. [CrossRef] [PubMed]

70. Stevens, B.; Allen, N.J.; Vazquez, L.E.; Howell, G.R.; Christopherson, K.S.; Nouri, N.; Micheva, K.; Melahow, A.; Huberman, A.D.; Stafford, B.; et al. The classical complement cascade mediates CNS synapse elimination. *Cell* 2007, 131, 1164–1178. [CrossRef]

71. Duan, M.; Yao, H.; Cai, Y.; Liao, K.; Seth, P.; Buch, S. HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-KBYY1 pathway. *Curr. HIV Res.* 2014, 12, 189–200. [CrossRef]

72. Mishra, N.; Mohata, M.; Aggarwal, H.; Chaudhary, O.; Das, B.K.; Sinha, S.; Hazarika, A.; Luthra, K. Expression of complement receptor 3 (CR3) and regulatory protein CD46 on dendritic cells of antiretroviral naive and treated HIV-1 infected individuals: Correlation with immune activation status. *Mol. Immunol.* 2018, 96, 83–87. [CrossRef]

73. McGuire, J.L.; Gill, A.J.; Douglas, S.D.; Kolson, D.L. The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth. *J. Neurovirol.* 2016, 22, 823–830. [CrossRef] [PubMed]

74. Miller, E.K.; Cohen, J.D. An integrative theory of prefrontal cortex function. *Annu. Rev. Neurosci.* 2001, 24, 167–202. [CrossRef]

75. Hersch, S.M.; White, E.L. Quantification of synapses formed with apical dendrites of Golgi-impregnated pyramidal cells: Variability in thalamocortical inputs, but consistency in the ratios of asymmetrical to symmetrical synapses. *Neuroscience* 1981, 8, 1043–1051. [CrossRef]

76. Santana, N.; Artigas, F. Laminar and cellular distribution of monoamine receptors in rat medial prefrontal cortex. *Front. Neuroanat.* 2017, 11, 87. [CrossRef] [PubMed]

77. McLaurin, K.A.; Harris, M.; Madormo, V.; Harrod, S.B.; Mactutus, C.F.; Booze, R.M. HIV-associated apathy/depression and neurocognitive impairments reflect persistent dopamine deficits. *Cells* 2021, 10, 2158. [CrossRef] [PubMed]

78. Saloner, R.; Cherney, M.; Iudicello, J.E.; Heaton, R.K.; Letendre, S.L.; Ellis, R.J. Cerebrospinal fluid norepinephrine and neurocognition in HIV and methamphetamine dependence. *JADIS J. Acquir. Immune Defic. Syndr.* 2020, 85, e12–e22. [CrossRef]

79. Shah, S.; Sinharay, S.; Matsuda, K.; Schreiber-Stainthorp, W.; Muthusamy, S.; Lee, D.; Wakim, P.; Hirsch, V.; Nath, A.; Di Mascio, M.; et al. Potential mechanism for HIV-associated depression: Upregulation of serotonin transporters in SIV-Infected macaques detected by 11C-DASB PET. *Front. Psychiatry* 2019, 10, 362. [CrossRef]
80. Denton, A.R.; Samaranayake, S.A.; Kirchner, K.N.; Roscoe, R.F.; Berger, S.N.; Harrod, S.B.; Mactutus, C.F.; Hashemi, P.; Booze, R.M. Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure. *J. Neurovirol.* 2019, 25, 540–550. [CrossRef]

81. Peters, A.; Kaiserman-Abramof, I.R. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. *Am. J. Anat.* 1970, 127, 321–355. [CrossRef] [PubMed]

82. Arellano, J.I.; Espinosa, A.; Fairen, A.; Yuste, R.; Defelipe, J. Non-synaptic dendritic spines in neocortex. *Neuroscience* 2007, 145, 464–469. [CrossRef]

83. Harris, K.M.; Stevens, J.K. Dendritic spines of rat cerebellar Purkinje cells: Serial electron microscopy with reference to their biophysical characteristics. *J. Neurosci.* 1988, 8, 4455–4469. [CrossRef] [PubMed]

84. Harris, K.M.; Stevens, J.K. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: Serial electron microscopy with reference to their biophysical characteristics. *J. Neurosci.* 1989, 9, 2982–2997. [CrossRef] [PubMed]

85. Araya, R.; Vogels, T.P.; Yuste, R. Activity-dependent dendritic spine neck changes are correlated with synaptic strength. *Proc. Natl. Acad. Sci. USA* 2014, 111, E2895–E2904. [CrossRef]

86. Cirino, T.J.; Harden, S.W.; McLaughlin, J.P.; Frazier, C.J. Region-specific effects of HIV-1 Tat on intrinsic electrophysiological properties of pyramidal neurons in mouse prefrontal cortex and hippocampus. *J. Neurophysiol.* 2020, 123, 1332–1341. [CrossRef]

87. Kim, H.J.; Martemyanov, K.A.; Thayer, S.A. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. *J. Neurosci.* 2008, 28, 12604–12613. [CrossRef]

88. Eckard, A.R.; Rosebush, J.C.; O’Riordan, M.A.; Graves, C.C.; Alexander, A.; Grover, A.K.; Lee, S.T.; Habib, J.G.; Ruff, J.H.; Chahroudi, A.; et al. Neurocognitive dysfunction in HIV-infected youth: Investigating the relationship with immune activation. *Antivir. Ther.* 2017, 22, 669–680. [CrossRef] [PubMed]

89. Augustemak de Lima, L.R.; Petroski, E.L.; Petroski, E.L.; Moreno, Y.M.F.; Silva, D.A.S.; Trindade, E.B.D.M.S.; Carvalho, A.P.D.; Back, I.D.C. Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIve Health Study. *PloS ONE* 2018, 13, e0190785. [CrossRef] [PubMed]

90. Blokhuis, C.; Peeters, C.F.W.; Cohen, S.; Scherbier, H.J.; Kuijpers, T.W.; Reiss, P.; Kootstra, N.A.; Teunissen, C.E.; Pajkrt, D. Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. *Sci. Rep.* 2019, 9, 8004. [CrossRef]

91. McCoig, C.; Castrejón, M.M.; Saavedra-Lozano, J.; Castaño, E.; Báez, C.; Lanier, E.R.; Sáez-Llorens, X.; Ramilo, O. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. *Pediatr. Infect. Dis. J.* 2004, 23, 114–118. [CrossRef]